Recent advancements in genome editing techniques, namely CRISPR/Cas9, have greatly facilitated cell line engineering, gene targeting, and the development of transgenic models. However, identification of correctly targeted cells remains a significant bottleneck for large-scale projects.
To remove this hurdle, Azenta Life Sciences, formerly GENEWIZ developed genoTYPER-NEXT™, a proprietary NGS-based assay ideal for ultra-sensitive, high-throughput, sample-to-answer genotyping projects. This tool is more effective and efficient than T7E1, TIDE, and IDAA assays for screening targeted cell lines.
Case Study | Rapid, Scalable, and Ultra-Sensitive Validation of Allele-Specific Gene Editing Events with genoTYPER-NEXT™
Discover the powerful capabilities of genoTYPER-NEXT in this illuminating case study and learn how this high-throughput assay allows rapid and accurate genotyping of CRISPR-edited cell lines.
Webinar | Rapid and Sensitive Validation of Gene Editing with Novel NGS Assays
Learn about current techniques to validate gene edits and how recent advancements in next generation sequencing are improving the sensitivity and scalability of screening genomic manipulations.
Blog | NGS, qPCR, or Sanger Sequencing: An Assay Selection Guide
This selection guide offers practical information about PCR + Sanger, qPCR, and NGS approaches to help you determine which assay best suits your project requirements, along with an interactive assay selection tool to aid your decision making.